Schott Pharma stock gains as JPMorgan starts coverage with Overweight rating
Published on 09/17/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Schott Pharma stock (ISIN DE000A3ENQ51) is trading close to its recent 52-week high after JPMorgan initiated coverage with an Overweight rating and a price target of EUR 27.10 on September 15, 2026, giving investors a fresh catalyst for the shares.
JPMorgan starts Schott Pharma with Overweight
According to Aktiencheck on September 16, 2026, JPMorgan analyst Philip Omnou initiated coverage of Schott Pharma with an Overweight rating and set a price target of EUR 27.10 for the stock.
The same analysis explains that Omnou sees an average annual earnings growth potential of 14 percent for Schott Pharma through 2029, underpinning the positive stance on the company’s long-term prospects.Aktiencheck
As wallstreet-online reported on September 17, 2026, the EUR 27.10 target implies a further upside of around 18 percent from the share price level discussed in that note, highlighting that the new analyst coverage has sparked additional price imagination among investors.
Stock trades near 52-week high after the call
Per Xetra trading data cited by ad-hoc-news on September 16, 2026, Schott Pharma stock was quoted at EUR 23.15 on Xetra around 09:28 a.m. local time, after opening at EUR 23.30 and trading in an intraday range between EUR 23.10 and EUR 23.30.
The same report notes that the shares reached a 52-week high of EUR 23.85 on September 15, 2026, so the EUR 23.15 level on September 16, 2026 left the stock about 3 percent below that recent peak while maintaining a strong year-to-date gain of more than 50 percent in the SDAX index environment.ad-hoc-news
In a separate quote overview, ad-hoc-news reports that Schott Pharma stock closed at EUR 23.35 on September 16, 2026 on its Frankfurt listing, matching the prior close and trading between an intraday low of EUR 23.05 and an intraday high of EUR 23.35 during that session.
Market commentary from wallstreet-online indicates that Schott Pharma shares reacted positively to the initial Overweight rating, with prices around EUR 23.00 and a gain of 0.55 percent quoted on Lang & Schwarz at 07:45 a.m. local time on September 17, 2026, suggesting that investors welcomed the new coverage.
Analyst view ties into long-term growth story
Analyst Philip Omnou’s projection of 14 percent average annual earnings growth through 2029 provides a quantitative long-term framework for Schott Pharma’s investment case, tying the Overweight rating and the EUR 27.10 price target directly to expected profit expansion.Aktiencheck
As finanzen.ch highlighted on September 15, 2026, Omnou’s thesis rests on structural trends in injectable medicines and Schott Pharma’s leading position as a supplier of high-quality containment and delivery solutions, which together are expected to support this mid-teens earnings growth trajectory.
From an investor perspective, the combination of a double-digit earnings growth outlook and a price target that still sits roughly 18 percent above the recent trading level means that the JPMorgan call not only validates Schott Pharma’s business model but also suggests further upside potential if the company delivers on the projected growth path.
Stock level and market metrics
Based on the Xetra data reported by ad-hoc-news, the Schott Pharma share price of EUR 23.15 on September 16, 2026 on Xetra sits just below the EUR 23.85 52-week high recorded on September 15, 2026, illustrating how the analyst coverage has coincided with the stock moving close to a new yearly high.
The same coverage mentions that Schott Pharma’s year-to-date performance in the SDAX index environment exceeds 50 percent as of mid-September 2026, indicating that the stock has already delivered a substantial return compared with the start of the year while still leaving room relative to the EUR 27.10 JPMorgan target.ad-hoc-news
In the same analyst note summarized by finanzen.ch, JPMorgan emphasizes structural demand for injectable drugs and Schott Pharma’s market leadership as key drivers behind the growth outlook, which can help investors understand why the bank considers the valuation attractive even after the strong share-price rally year-to-date.
Closing price and investor takeaway
Schott Pharma stock last closed at EUR 23.35 on its Frankfurt listing on September 16, 2026, with an intraday trading range between EUR 23.05 and EUR 23.35 and the closing level effectively flat versus the prior session, keeping the shares only about 2 percent below the recent 52-week high of EUR 23.85 set on September 15, 2026.
Schott Pharma stock - key data
- Company: Schott Pharma AG & Co. KGaA
- ISIN: DE000A3ENQ51
- WKN: A3ENQ5
- Ticker: 1SXP
- Trading venue: Xetra
- Price (as of September 16, 2026, 09:28): 23.15 EUR
- Market capitalization: not specified in available sources (as of September 16, 2026)
- Sector / Industry: Pharmaceuticals, injectable drug delivery solutions
- Index membership: SDAX
